RISERS
Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) saw shares shoot up over 55% to US$9.61 as it reported top line results in cannabidiol gel ZYN002 open label phase 2 study in children with Fragile X syndrome. The study successfully met the primary endpoint.
The firm is a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced cannabinoid treatments.
Exa Corp (NASDAQ:EXA) added almost 41% at US$24.25 after Dassault Systèmes announced plans to acquire the group for $24.25 per share in cash.
FALLERS
GoPro Inc (NASDAQ:GPRO) shares shed 1.72% to US$11.49 as the firm confirmed the release of Hero 6 and GoPro Fusion. The company hopes the new cameras will lead to strong holiday season sales.